GSTP1 Ile105Val polymorphism and prostate cancer risk: evidence from a meta-analysis.
BACKGROUND: Glutathione S-transferase P1 (GSTP1) is thought to be involved in the detoxification of reactive carcinogen metabolites. Numerous epidemiological studies have evaluated the association of GSTP1 Ile105Val polymorphism with the risk of prostate cancer. However, the results remain inconclus...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3747220?pdf=render |
| _version_ | 1819289901249593344 |
|---|---|
| author | Bingbing Wei You Zhou Zhuoqun Xu Jun Ruan Huan Cheng Ming Zhu Qiang Hu Ke Jin Zhiqiang Yan Deqi Zhou Feng Xuan Hongyi Zhou Zhirong Wang Xing Huang Qiang Wang |
| author_facet | Bingbing Wei You Zhou Zhuoqun Xu Jun Ruan Huan Cheng Ming Zhu Qiang Hu Ke Jin Zhiqiang Yan Deqi Zhou Feng Xuan Hongyi Zhou Zhirong Wang Xing Huang Qiang Wang |
| author_sort | Bingbing Wei |
| collection | DOAJ |
| description | BACKGROUND: Glutathione S-transferase P1 (GSTP1) is thought to be involved in the detoxification of reactive carcinogen metabolites. Numerous epidemiological studies have evaluated the association of GSTP1 Ile105Val polymorphism with the risk of prostate cancer. However, the results remain inconclusive. To derive a more precise estimation, a meta-analysis was performed. METHODOLOGY/PRINCIPAL FINDINGS: A comprehensive search was conducted to identify the eligible studies. We used odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of the relationship. The overall association was not significant (Val/Val vs. Ile/Ile OR = 1.06, 95% CI = 0.90-1.25, P = 0.50; Val/Val vs. Val/Ile+Ile/Ile: OR = 1.07, 95% CI = 0.91-1.25, P = 0.44). In subgroup analyses by ethnicity and prostate cancer grade, the similar results were observed. However, in stratified analysis by clinical stage, we found a significant association with low-stage prostate cancer (Val/Val vs. Ile/Ile: OR = 2.70, 95% CI = 1.73-4.22, P<0.001; Val/Val vs. Val/Ile+Ile/Ile: OR = 2.14, 95% CI = 1.38-3.33, P = 0.001). Moreover, there was no statistically significant evidence of multiplicative interactions neither between the GSTP1 Ile105Val polymorphism and GSTM1, nor between smoking status and GSTP1 on prostate cancer risk. CONCLUSIONS: This meta-analysis showed that GSTP1 Ile105Val polymorphism might not be significantly associated with overall prostate cancer risk. Further stratified analyses showed a significant association with low-stage prostate cancer. |
| first_indexed | 2024-12-24T03:14:12Z |
| format | Article |
| id | doaj.art-a4bf7d0480db4e63b3e054d077e58114 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-24T03:14:12Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-a4bf7d0480db4e63b3e054d077e581142022-12-21T17:17:42ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0188e7164010.1371/journal.pone.0071640GSTP1 Ile105Val polymorphism and prostate cancer risk: evidence from a meta-analysis.Bingbing WeiYou ZhouZhuoqun XuJun RuanHuan ChengMing ZhuQiang HuKe JinZhiqiang YanDeqi ZhouFeng XuanHongyi ZhouZhirong WangXing HuangQiang WangBACKGROUND: Glutathione S-transferase P1 (GSTP1) is thought to be involved in the detoxification of reactive carcinogen metabolites. Numerous epidemiological studies have evaluated the association of GSTP1 Ile105Val polymorphism with the risk of prostate cancer. However, the results remain inconclusive. To derive a more precise estimation, a meta-analysis was performed. METHODOLOGY/PRINCIPAL FINDINGS: A comprehensive search was conducted to identify the eligible studies. We used odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of the relationship. The overall association was not significant (Val/Val vs. Ile/Ile OR = 1.06, 95% CI = 0.90-1.25, P = 0.50; Val/Val vs. Val/Ile+Ile/Ile: OR = 1.07, 95% CI = 0.91-1.25, P = 0.44). In subgroup analyses by ethnicity and prostate cancer grade, the similar results were observed. However, in stratified analysis by clinical stage, we found a significant association with low-stage prostate cancer (Val/Val vs. Ile/Ile: OR = 2.70, 95% CI = 1.73-4.22, P<0.001; Val/Val vs. Val/Ile+Ile/Ile: OR = 2.14, 95% CI = 1.38-3.33, P = 0.001). Moreover, there was no statistically significant evidence of multiplicative interactions neither between the GSTP1 Ile105Val polymorphism and GSTM1, nor between smoking status and GSTP1 on prostate cancer risk. CONCLUSIONS: This meta-analysis showed that GSTP1 Ile105Val polymorphism might not be significantly associated with overall prostate cancer risk. Further stratified analyses showed a significant association with low-stage prostate cancer.http://europepmc.org/articles/PMC3747220?pdf=render |
| spellingShingle | Bingbing Wei You Zhou Zhuoqun Xu Jun Ruan Huan Cheng Ming Zhu Qiang Hu Ke Jin Zhiqiang Yan Deqi Zhou Feng Xuan Hongyi Zhou Zhirong Wang Xing Huang Qiang Wang GSTP1 Ile105Val polymorphism and prostate cancer risk: evidence from a meta-analysis. PLoS ONE |
| title | GSTP1 Ile105Val polymorphism and prostate cancer risk: evidence from a meta-analysis. |
| title_full | GSTP1 Ile105Val polymorphism and prostate cancer risk: evidence from a meta-analysis. |
| title_fullStr | GSTP1 Ile105Val polymorphism and prostate cancer risk: evidence from a meta-analysis. |
| title_full_unstemmed | GSTP1 Ile105Val polymorphism and prostate cancer risk: evidence from a meta-analysis. |
| title_short | GSTP1 Ile105Val polymorphism and prostate cancer risk: evidence from a meta-analysis. |
| title_sort | gstp1 ile105val polymorphism and prostate cancer risk evidence from a meta analysis |
| url | http://europepmc.org/articles/PMC3747220?pdf=render |
| work_keys_str_mv | AT bingbingwei gstp1ile105valpolymorphismandprostatecancerriskevidencefromametaanalysis AT youzhou gstp1ile105valpolymorphismandprostatecancerriskevidencefromametaanalysis AT zhuoqunxu gstp1ile105valpolymorphismandprostatecancerriskevidencefromametaanalysis AT junruan gstp1ile105valpolymorphismandprostatecancerriskevidencefromametaanalysis AT huancheng gstp1ile105valpolymorphismandprostatecancerriskevidencefromametaanalysis AT mingzhu gstp1ile105valpolymorphismandprostatecancerriskevidencefromametaanalysis AT qianghu gstp1ile105valpolymorphismandprostatecancerriskevidencefromametaanalysis AT kejin gstp1ile105valpolymorphismandprostatecancerriskevidencefromametaanalysis AT zhiqiangyan gstp1ile105valpolymorphismandprostatecancerriskevidencefromametaanalysis AT deqizhou gstp1ile105valpolymorphismandprostatecancerriskevidencefromametaanalysis AT fengxuan gstp1ile105valpolymorphismandprostatecancerriskevidencefromametaanalysis AT hongyizhou gstp1ile105valpolymorphismandprostatecancerriskevidencefromametaanalysis AT zhirongwang gstp1ile105valpolymorphismandprostatecancerriskevidencefromametaanalysis AT xinghuang gstp1ile105valpolymorphismandprostatecancerriskevidencefromametaanalysis AT qiangwang gstp1ile105valpolymorphismandprostatecancerriskevidencefromametaanalysis |